Replies to post #3483 on GTC Biotherapeutics (fka GTCB)

[ThomasS]

Wow, this board is heating up... and all regarding old thoughts.
I do not believe that ATRYN's prospects have much to do with a possible sale or take-out of GTCB as it is all about the platform now.
That being said, GTCB is clearly undervalued "just" from the point-of-view that ATRYN revs will markedly surpass the current market cap...